Equities research analysts at EF Hutton Acquisition Co. I assumed coverage on shares of Clene (NASDAQ:CLNN – Get Rating) in a research report issued on Wednesday, Benzinga reports. The brokerage set a “buy” rating and a $13.00 price target on the stock.
Several other research analysts have also issued reports on CLNN. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of Clene in a research report on Tuesday. Roth Capital reiterated a “buy” rating on shares of Clene in a report on Monday, February 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.00.
Clene Stock Up 3.8 %
NASDAQ:CLNN opened at $1.35 on Wednesday. Clene has a 12-month low of $0.87 and a 12-month high of $5.13. The firm has a market capitalization of $99.66 million, a P/E ratio of -3.55 and a beta of 0.39. The stock’s fifty day simple moving average is $1.31 and its 200-day simple moving average is $1.59.
Institutional Trading of Clene
Clene Company Profile
Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
- Get a free copy of the StockNews.com research report on Clene (CLNN)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Clene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clene and related companies with MarketBeat.com's FREE daily email newsletter.